Expected Completion of Sparsentan Phase 3 IgA Nephropathy Trial
Jul 1, 2026, 4:00:00 AM UTC
Summary
Travere Therapeutics is conducting a global Phase 3 clinical trial (PROTECT, NCT03762850) evaluating sparsentan, a dual angiotensin receptor blocker and endothelin receptor antagonist, in patients with IgA Nephropathy at high risk of disease progression. The study compares sparsentan to irbesartan, the current standard of care, with primary endpoints including change in proteinuria and estimated glomerular filtration rate. The trial, which includes an open-label extension and a sub-study with dapagliflozin, is expected to complete on July 1, 2026. Sparsentan is being developed as a potential first-in-class treatment for IgA Nephropathy.
Company
TRAVERE THERAPEUTICS INC (TVTX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.retrophin.comSimilar Events
Expected Trial Completion for Sparsentan in Pediatric Proteinuric Glomerular Diseases
Travere Therapeutics is conducting a Phase 2 multicenter, open-label clinical trial evaluating Sparsentan in approximately 67 pediatric patients with various proteinuric glomerular diseases, including FSGS, MCD, IgAN, IgAV, and Alport syndrome. The study aims to assess long-term safety, tolerability, and efficacy, with completion expected on April 12, 2027. Sparsentan is a dual endothelin and angiotensin receptor antagonist being developed for rare kidney disorders.
trial completionCompletion of Phase 3 Sparsentan Trial in FSGS
Travere Therapeutics is expected to complete its Phase 3 clinical trial of sparsentan in patients with primary focal segmental glomerulosclerosis (FSGS) by February 1, 2026. The global, randomized, double-blind study compares sparsentan, a dual-acting angiotensin and endothelin receptor antagonist, to irbesartan. The trial's primary completion date refers to the end of the double-blind phase, with an open-label extension to follow. Sparsentan is being developed as a potential treatment for FSGS, a rare kidney disorder.
trial completionSPARVASC Phase 2 trial completion for sparsentan in ANCA-associated vasculitis
The Phase 2 SPARVASC clinical trial (NCT05630612), sponsored by the University of Edinburgh and involving Travere Therapeutics (TVTX), is expected to complete on September 1, 2027. The study evaluates the efficacy of sparsentan, an endothelin-A and angiotensin-1 receptor antagonist, versus irbesartan in patients with ANCA-associated vasculitis in long-term remission. The trial aims to assess whether sparsentan improves endothelial function and reduces cardiovascular risk in this patient population. Sparsentan is an investigational dual endothelin and angiotensin receptor antagonist being developed for rare kidney and vascular diseases.
trial completionAtacicept Phase 3 Trial Completion in IgA Nephropathy
Vera Therapeutics is conducting a pivotal Phase 3 clinical trial of atacicept in patients with IgA nephropathy (IgAN) and persistent proteinuria. The study, which began in May 2023, is expected to complete on July 1, 2028. The trial evaluates atacicept’s efficacy and safety versus placebo, with primary endpoints including reduction in proteinuria and assessments of kidney function and immunological markers. Atacicept is a recombinant fusion protein targeting B-cell activation, and is being developed as a potential first-in-class therapy for IgAN, a rare kidney disorder.
trial completion